특집 -비만 : 비만의 행동중재와 약물치료 = Special Review : Behavioral Intervention and Anti-Obesity Drug Therapy

다국어 초록 (Multilingual Abstract)

Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012. (Korean J Med 2013; 84:624-628)

참고문헌 (Reference)

1 김경수, "비만의 약물치료: 허가된 약물을 중심으로" 대한비만학회 21 (21): 197-202, 2012

2 Torgerson JS, "XENical in the prevention of diabetes in obese subjects(XENDOS)study : a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients" 27 : 155-161, 2004

3 Moyer VA, "U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement" 157 : 373-378, 2012

4 Unick JL, "The long-term effectiveness of a lifestyle intervention in severely obese individuals" 126 : 236-242, 2013

5 Li G, "The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study : a 20-year follow-up study" 371 : 1783-1789, 2008

6 Deedwania PC, "Risk of diabetes and cardiovascular disease : best to return back to the basics : comment on"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus"" 170 : 1575-1577, 2010

7 Kang JG, "Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity" 12 : 876-882, 2010

8 Kushner RF, "Pharmacologic management of obesity" 58 : 140-143, 2012

9 Ahmed MH, "Orlistat and calcium oxalate crystalluria : an association that needs consideration" 32 : 1019-1021, 2010

10 Ryan DH, "Nonsurgical weight loss for extreme obesity in primary care settings : results of the Louisiana Obese Subjects Study" 170 : 146-154, 2010

11 Gadde KM, "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial" 377 : 1341-1352, 2011

12 James WP, "Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects" 363 : 905-917, 2010

13 Apovian C, "A randomized, phase 3Trial of naltrexone SR/Bupropion SR on weight and obesity-related risk factors (COR-II)" 2013

14 Fidler MC, "A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults : the BLOSSOM Trial" 96 : 3067-3077, 2011